These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 9440663)

  • 1. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
    Bayoumi AM; Redelmeier DA
    AIDS; 1998 Aug; 12(12):1503-12. PubMed ID: 9727572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
    Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
    Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.
    Scharfstein JA; Paltiel AD; Weinstein MC; Seage GR; Losina E; Craven DE; Freedberg KA
    Int J Technol Assess Health Care; 1999; 15(3):531-47. PubMed ID: 10874380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.
    Freedberg KA; Cohen CJ; Barber TW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(4):275-82. PubMed ID: 9292586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.
    Freedberg KA; Hardy WD; Holzman RS; Tosteson AN; Craven DE
    Med Decis Making; 1996; 16(1):29-35. PubMed ID: 8717596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis.
    Yazdanpanah Y; Goldie SJ; Paltiel AD; Losina E; Coudeville L; Weinstein MC; Gerard Y; Kimmel AD; Zhang H; Salamon R; Mouton Y; Freedberg KA
    Clin Infect Dis; 2003 Jan; 36(1):86-96. PubMed ID: 12491207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.
    Sackoff J; McFarland J; Su S; Bryan E
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):387-92. PubMed ID: 9833748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis of opportunistic infections in adults and children with HIV infection.
    AIDS Inst Newsl; 1995 Jun; ():1-12. PubMed ID: 11367408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.
    Sendi PP; Craig BA; Meier G; Pfluger D; Gafni A; Opravil M; Battegay M; Bucher HC
    J Antimicrob Chemother; 1999 Dec; 44(6):811-7. PubMed ID: 10590283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing opportunistic infections.
    Cheng B
    PI Perspect; 1995 May; (no 16):14-5. PubMed ID: 11362422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
    MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease.
    Hoffmann T; Brunner H
    Eur J Health Econ; 2004 Jun; 5(2):129-35. PubMed ID: 15452749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.
    Moore RD; Chaisson RE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):15-21. PubMed ID: 9377120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.
    Johri M; David Paltiel A; Goldie SJ; Freedberg KA
    Med Care; 2002 May; 40(5):429-41. PubMed ID: 11961477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.
    Chung JB; Armstrong K; Schwartz JS; Albert D
    Arthritis Rheum; 2000 Aug; 43(8):1841-8. PubMed ID: 10943875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
    Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
    Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates.
    Wynia MK; Ioannidis JP; Lau J
    AIDS; 1998 Jul; 12(11):1317-25. PubMed ID: 9708411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
    Yazdanpanah Y; Losina E; Anglaret X; Goldie SJ; Walensky RP; Weinstein MC; Toure S; Smith HE; Kaplan JE; Freedberg KA;
    AIDS; 2005 Aug; 19(12):1299-308. PubMed ID: 16052085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.